Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
16.31
-0.02 (-0.12%)
Dec 20, 2024, 4:00 PM EST - Market closed
Anika Therapeutics Revenue
Anika Therapeutics had revenue of $38.75M in the quarter ending September 30, 2024, a decrease of -6.54%. This brings the company's revenue in the last twelve months to $164.17M, up 0.52% year-over-year. In the year 2023, Anika Therapeutics had annual revenue of $166.66M with 6.67% growth.
Revenue (ttm)
$164.17M
Revenue Growth
+0.52%
P/S Ratio
1.46
Revenue / Employee
$459,854
Employees
357
Market Cap
238.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 166.66M | 10.43M | 6.67% |
Dec 31, 2022 | 156.24M | 8.44M | 5.71% |
Dec 31, 2021 | 147.79M | 17.34M | 13.29% |
Dec 31, 2020 | 130.46M | 15.85M | 13.83% |
Dec 31, 2019 | 114.61M | 9.06M | 8.58% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
High Tide | 370.02M |
Heron Therapeutics | 137.74M |
Pulmonx | 79.30M |
Electromed | 57.06M |
Cidara Therapeutics | 44.65M |
BGM Group | 29.87M |
Artiva Biotherapeutics | 2.60M |
ANIK News
- 4 weeks ago - Anika To Participate in December 2024 Investor Conferences - GlobeNewsWire
- 7 weeks ago - Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics - PRNewsWire
- 7 weeks ago - Anika Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical - GlobeNewsWire
- 2 months ago - Anika Announces Third Quarter 2024 Results Conference Call Date - GlobeNewsWire
- 2 months ago - Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Anika Therapeutics, Inc (ANIK) Q2 2024 Earnings Call Transcript - Seeking Alpha